Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer (DESKTOPIII)
A Randomized Multicenter Study to Compare the Efficacy of Additional Tumor Debulking Surgery vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Sponsor: AGO Study Group
A NA clinical study on Fallopian Tube Cancer and Ovarian Cancer, this trial is completed. The trial is conducted by AGO Study Group and has accumulated 11 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Feb 2022 — Jul 2024 [monthly]
Completed NA
-
Feb 2021 — Feb 2022 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting NA
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Jul 2018 — Aug 2020 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
Phase: PHASE3 → NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jul 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AGO Study Group
- ARCAGY/ GINECO GROUP
- Cancer Research UK
- Grupo Español de Investigación en Cáncer de Ovario
- Shanghai Gynecologic Oncology Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus, Denmark , Aviano, Italy , Bad Homburg, Germany , Badalona, Spain , Barcelona, Spain , Berlin, Germany , Birmingham, United Kingdom , Bordeaux, France , Caen, France and 64 more locations